Wird geladen...
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
LESSONS LEARNED. Due to evolving imaging criteria in brain tumors and variation in magnetic resonance imaging evaluation, it is not ideal to use response rate as a primary objective. Future studies involving antiangiogenic agents should use overall survival. Disease‐expected toxicities should be con...
Gespeichert in:
| Veröffentlicht in: | Oncologist |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
AlphaMed Press
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6156179/ https://ncbi.nlm.nih.gov/pubmed/29666296 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0149 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|